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instrumenting a narrow posterior interspace
might cause more, and not less, pain, par-
ticularly if an endoscopic clamp, a 5-mm
video camera, and an 11-mm endostapler
are all placed through the same incision.
Furthermore, I anticipate technical lim-
itations with the ability to perform an ex-
ploratory thoracoscopy for traumatic injury
through a single incision in the midthorax.
During the course of elective surgical in-
tervention for bullous disease, interstitial
disease, or a pulmonary nodule, a mid-
scapular incision is recommended for le-
sions in the superior or apical segments,
and a posterior axillary incision is recom-
mended for lingular or middle lobe le-
sions.1,2 There is no such preoperative tar-
get in the case of traumatic injury, and
thoracoscopy is a true exploration. The en-
tire pleural cavity must be inspected, and
many times the video camera is moved
from one port to another to obtain a com-
prehensive view. I suspect that in all but the
most limited injury, it would be unwise to
limit the exploration to a single point of
view. However, the uniportal technique
might be valuable as an initial diagnostic
maneuver, and if the entire injury is com-
fortably visualized and if endoscopic sta-
pled resection is not required, the uniportal
technique might suffice.
Because of concerns regarding the ana-
tomic constraints of the posterior approach
and the potential for a less than complete
trauma exploration, I would only consider
the uniportal approach of potential value as
an initial diagnostic maneuver, and I would
continue to approach most patients with
complex penetrating chest injury with a
conventional 3-port approach or open tho-
racotomy.
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Anticoagulation after bioprosthetic
aortic valve replacement
To the Editor:
We read with interest the letter by di Marco
and associates1 concerning anticoagulation
after bioprosthetic aortic valve replacement.
We also performed a survey of such antico-
agulation practice among UK consultant car-
diothoracic surgeons.2 This highlights a sim-
ilar disparity between the accepted guidelines
and actual practice in the postoperative man-
agement of patients undergoing bioprosthetic
aortic valve replacement, without comorbidi-
ties or risk factors that necessitate anticoagu-
lation.
In our survey, only 16% of consultants
(16/97) adhered to the comparable American
College of Chest Physicians (ACCP)3 or
American College of Cardiology/American
Heart Association guidelines.4 The major-
ity of consultants (51/97 [52%]) never used
warfarin at all postoperatively, of whom 40
of 51 (78%) initiated antiplatelet therapy
instead. The other 22% (11/51) used nei-
ther antiplatelet nor anticoagulation ther-
apy postoperatively.
It is important to note that the ACCP
guidelines recommending 3 months of an-
ticoagulation postoperatively are termed a
“Grade 2C Recommendation.” This means
that the evidence for the recommendation
came from observational studies or case
series. As such, the ACCP accepts that the
evidence is of low quality, and that there is
uncertainty in the estimates of benefits,
risks, and burden. The ACCP is aware this
is a very weak recommendation, and other
alternatives may be equally reasonable.5
Given that so few surgeons seem to be
following these guidelines, we await the
updated European Society of Cardiology
recommendations with anticipation.
Perhaps the prospective randomized
clinical trial being undertaken by di Marco
and associates1 will provide stronger evi-
dence and clarify a controversial area in the
management of bioprosthetic heart valve
replacement.
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See related editorial on page 1223.
References
1. di Marco F, Meneghetti G, Gerosa G. Early
anticoagulation after aortic valve replacement
with bioprostheses: time to abandon it?
J Thorac Cardiovasc Surg. 2005;130:1482-3.
2. Vaughan P, Waterworth P. An audit of anti-
coagulation practice among UK cardiotho-
racic consultant surgeons following valve
replacement/repair. J Heart Valve Dis. 2005;14:
576-82.
3. Stein PD, Alpert JS, Bussey HI, Dalen JE,
Turpie AGG. Antithrombotic therapy in pa-
tients with mechanical and biological pros-
thetic heart valves. Chest. 2001;119:220-7.
4. Bonow RO, Carabello B, de Leon AC Jr,
Edmunds LH Jr, Fedderly BJ, Freed MD,
et al. Guidelines for the management of pa-
tients with valvular heart disease: executive
summary. A report of the American College of
Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on
Management of Patients with Valvular Heart
Disease). Circulation. 1998;98:1949-84.
5. Guyatt G, Gutterman D, Baumann MH,
Addrizzo-Harris D, Hylek EM, Phillips B,
et al. Grading strength of recommendations and
quality of evidence in clinical guidelines. Re-
port from an American College of Chest Phy-
sicians’ Task Force. Chest. 2006;129:174-81.
doi:10.1016/j.jtcvs.2005.11.056
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 6 1425
